상세 보기
Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis
- Lee, Ji Yun;
- Lim, Sung Hee;
- Kim, Seok Jin;
- Lee, Ga Yeon;
- Lee, Jung Eun;
- ... Choi, Jin-Oh;
- ... Kim, Jung-Sun;
- ... Kim, Hee-Jin;
- ... Lee, Soo-Youn;
- ... Min, Ju-Hong;
- ... Kim, Kihyun;
- 외 1명
WEB OF SCIENCE
17SCOPUS
21초록
Bortezomib combination chemotherapy appears to be active in light chain (AL) amyloidosis with high rates of hematologic and organ response. We report a retrospective evaluation of the clinical outcome of treatment with bortezomib, melphalan, and prednisolone (VMP) as first-line chemotherapy in patients with AL amyloidosis who were ineligible for autologous stem cell transplant. Among the 19 patients included in this study, 90% had two or more involved organs and most of the patients had advanced stage AL amyloidosis (84% with 2004 Mayo Stage III and 92% with 2012 Mayo Stage III or IV). Sixteen (84%) patients had a hematologic response, including seven (37%) with complete response, with time to response of 1-3 months. Cardiac and renal responses were observed in 44% and 33% of patients, respectively. Estimated 2-year survival is 39%, and 5 patients (26%) died during therapy. The common grade 3-4 adverse events were thrombocytopenia, diarrhea and pneumonia. A once-weekly bortezomib is more feasible than twice-weekly regimen. Our results suggest that triplet regimen of VMP appears to be an effective regimen in advanced AL amyloidosis, but benefits in the patients with multi-organ dysfunction remain to be proven.
키워드
- 제목
- Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis
- 저자
- Lee, Ji Yun; Lim, Sung Hee; Kim, Seok Jin; Lee, Ga Yeon; Lee, Jung Eun; Choi, Jin-Oh; Kim, Jung-Sun; Kim, Hee-Jin; Lee, Soo-Youn; Min, Ju-Hong; Jeon, Eun-Seok; Kim, Kihyun
- 발행일
- 2014-12
- 유형
- Article
- 권
- 21
- 호
- 4
- 페이지
- 261 ~ 266
- 언어
- ENG
- 출판사
- Taylor & Francis
- 발행국가
- 영국
- 분량
- 6 페이지
- ISSN
- E 1744-2818
P 1350-6129